Indica Labs vs Proscia (2026)
Both sell a cleared platform for primary diagnosis with their own AI labeled research use only in the United States. Indica's HALO AP Dx is cleared with two named scanners (K232833 and K252762), and HALO AP, which runs Indica's Breast IHC, Lung PD-L1 and Prostate AI, is CE-IVDR marked in Europe. Proscia's Concentriq AP-Dx is cleared (K230839, and K261380 in August 2026, which added cloud deployment and a change control plan), supports more than 45 scanners and runs more than 230 applications from Proscia and other makers.
- You want HALO hosted on AWS inside an account you control.
- Two way integration with your laboratory information system matters.
- You want the platform maker's own AI, CE-IVDR marked in Europe, for breast IHC, lung PD-L1 and prostate.
- Scanner choice matters: more than 45 scanners are supported.
- You want many makers' applications on one platform.
- Your security review asks for SOC 2 Type II, ISO 27001 and ISO 13485, which Proscia names.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. Indica Labs and Proscia are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
| Fact | Indica Labs | Proscia |
|---|---|---|
| Primary category | Digital Pathology AI | Digital Pathology AI |
| Founded | 2007 | 2014 |
| Headquarters | Albuquerque, New Mexico, United States | Philadelphia, Pennsylvania, United States |
| Website | indicalab.com | proscia.com |
Side by Side
Select any grade to read the note behind it.
Each vendor in one paragraph
Written to be quoted whole. Each paragraph opens the AI Health Index profile of the vendor: what the product is, who buys it and what it does.
Albuquerque based digital pathology company whose HALO AP Dx platform is FDA 510(k) cleared for primary diagnosis with named scanners (K232833 with the Hamamatsu NanoZoomer S360MD; K252762 adding the Leica Aperio GT 450 DX). HALO AP, which runs Indica's own AI (Breast IHC AI, Lung PD-L1 AI, Prostate AI) and hosted third party AI, is CE-IVDR marked in Europe, the UK and Switzerland and research use only in the United States.
Source: AI Health Index, September 2026
Digital pathology software company whose Concentriq platform manages, displays and analyzes whole slide pathology images for clinical laboratories and life sciences organizations. Its diagnostic edition, Concentriq AP-Dx, is FDA 510(k) cleared (K230839 in 2024 and K261380 in August 2026, which added cloud deployment and a change control plan), Health Canada licensed and CE marked under the EU IVDR for primary diagnosis on FFPE surgical pathology slides; the research editions are labeled Research Use Only, a distinction the company draws explicitly.
Source: AI Health Index, September 2026
Questions buyers ask
How do Indica Labs and Proscia work with the EHR?
For Indica Labs, the HALO AP Dx page says the platform assembles cases from barcodes and LIS or LIMS data, keeps worklists updated from the LIS, generates the pathology report and sends it automatically to the LIS through an interface, and offers API-first connectivity; it is DICOM compliant and cleared for SVS and DICOM files from the Leica Aperio GT 450 DX.
With Proscia, the company states that AI recommended ancillary test requests flow back into the LIS rather than a separate ticket queue, which is a real workflow closure rather than a display feature. The platform also serves as a host environment for third party algorithms, with at least one external spatial biology vendor embedding its predictive biomarker technology into Concentriq. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 28, 2026. No vendor pays for placement.
How do Indica Labs and Proscia handle patient data?
In Indica Labs' case, the product pages state that HALO AP provides built-in compliance with FDA 21 CFR Part 11 (electronic records and audit trails), HIPAA and GDPR. Under Cloud Services the deployment sits in an AWS account the customer controls, which keeps slide images in the customer's tenancy rather than a vendor environment.
For Proscia, the platform page states that "everything in Concentriq stays within your organization, unless you give express permission to de-identify and share it to advance research", and that "your data is never used to train the models Concentriq runs". From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 28, 2026. No vendor pays for placement.
Which settings and specialties do Indica Labs and Proscia cover?
With Indica Labs, the company serves clinical laboratories, research institutes, contract research organizations and companion diagnostic development, with named clinical users including the National Cancer Institute, Nottingham University Hospitals and the University of Bern.
In Proscia's case, the clinical edition serves high volume diagnostic laboratories for primary diagnosis on scanned surgical pathology slides from FFPE tissue, and excludes frozen sections, cytology and non-FFPE hematopathology specimens; the research editions serve life sciences organizations for biomarker research, clinical trials and companion diagnostics. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 28, 2026. No vendor pays for placement.
What evidence is published for Indica Labs and Proscia?
For Indica Labs, the 510(k) clearances for HALO AP Dx rest on validation of the viewing platform for primary diagnosis, and the company names deployments at the National Cancer Institute, the University of Washington (40 percent AWS cost savings in four months, a vendor figure), Nottingham University Hospitals, the University of Bern and Source BioScience.
With Proscia, the earlier dermatopathology classifier was validated across two university hospitals and two commercial dermatopathology laboratories on more than 20,000 biopsy slides. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 28, 2026. No vendor pays for placement.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Digital Pathology AI page.
Each clearance covers the platform, not the AI, and is tied to named scanners. Neither publishes pricing. Rewritten 28 Sep 2026 after both records were reviewed.